Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Employment agrmnt
Appointed director
Consulting agrmnt
Director departure
|
|
THERALINK TECHNOLOGIES, INC. (OBMP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/21/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/15/2023 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 06/29/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...|
Docs:
|
"Theralink Technologies Appoints Faith Zaslavsky as Chief Executive Officer Golden, Colorado, June 27, 2023 — Theralink Technologies, Inc. , a precision oncology company with a novel phosphoprotein and protein assay for breast cancer in the process of merging with IMAC Holdings, Inc. , today announces the appointment of Faith Zaslavsky as its new Chief Executive Officer. Ms. Zaslavsky, who has served as the Company’ s President and Chief Operating Officer since December 2022, will assume this role effective June 26, 2023, replacing Mick Ruxin, M.D., who will transition to Theralink’ s Chief Medical Officer. “I am very excited to hand the reins to Faith as we take the strategic step to merge with IMAC,” commented Dr. Ruxin. “As we begin a new chapter of shifting our focus from research and d..." |
|
| 05/26/2023 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 05/26/2023 |
8-K
| Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits Interactive Data |
| 05/11/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 02/01/2023 |
8-K
| Quarterly results |
| 12/29/2022 |
10-K
| Annual Report for the period ended September 30, 2022 |
| 12/14/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 12/08/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/01/2022 |
8-K
| Quarterly results |
| 09/26/2022 |
4
| Schwartz Matthew Wilson (Director) has filed a Form 4 on THERALINK TECHNOLOGIES, INC.|
Txns:
| Acquired convertible notes
@ $0.0048, valued at
$0
Acquired 4,201,681 warrants
@ $0.0048, valued at
$20.2k
Granted 5,191,080 options to buy
@ $0.0036, valued at
$18.7k
|
|
| 09/22/2022 |
4
| FORS YVONNE (Director) has filed a Form 4 on THERALINK TECHNOLOGIES, INC.|
Txns:
| Granted 6,488,851 options to buy
@ $0.0036, valued at
$23.4k
|
|
| 09/21/2022 |
4
| Busch Jeffrey (Chairman of the Board) has filed a Form 4 on THERALINK TECHNOLOGIES, INC.|
Txns:
| Granted 469,738,712 options to buy
@ $0.0036, valued at
$1.7M
|
|
| 09/21/2022 |
4
| Chilcott, III Thomas E. (CFO) has filed a Form 4 on THERALINK TECHNOLOGIES, INC.|
Txns:
| Granted 94,545,096 options to buy
@ $0.0036, valued at
$340.4k
|
|
| 09/21/2022 |
4
| RUXIN MICHAEL I (CEO) has filed a Form 4 on THERALINK TECHNOLOGIES, INC.|
Txns:
| Granted 469,738,712 options to buy
@ $0.0036, valued at
$1.7M
|
|
| 09/16/2022 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 08/15/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/11/2022 |
8-K/A
| Quarterly results |
| 07/07/2022 |
8-K
| Quarterly results |
| 06/22/2022 |
4
| Holley Danica (Director) has filed a Form 4 on THERALINK TECHNOLOGIES, INC.|
Txns:
| Acquired convertible notes
@ $0.0048, valued at
$0
Acquired 2,100,840 warrants
@ $0.0048, valued at
$10.1k
|
|
| 06/21/2022 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 06/02/2022 |
DEF 14C
| Form DEF 14C - Other definitive information statements: |
| 05/23/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
| 05/20/2022 |
PRE 14C
| Form PRE 14C - Other preliminary information statements: |
| 05/17/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 04/05/2022 |
3
| Holley Danica (Director) has filed a Form 3 on THERALINK TECHNOLOGIES, INC. |
| 02/18/2022 |
10-Q
| Quarterly Report for the period ended December 31, 2021 |
| 02/15/2022 |
NT 10-Q
| Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB: |
| 02/03/2022 |
8-K
| Quarterly results |
| 01/05/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 12/30/2021 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 11/29/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
| 11/05/2021 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...|
Docs:
|
"THERALINK TECHNOLOGIES, INC. 2021 CONVERTIBLE PROMISSORY NOTE $[ ] Golden, Colorado Issue Date: NOVEMBer [ ], 2021",
"COMMON STOCK PURCHASE WARRANT THERALINK TECHNOLOGIES, inc. Warrant Shares: [ ] Issue Date: November [ ], 2021 THIS COMMON STOCK PURCHASE WARRANT certifies that, for value received, [ ] is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time after the Issue Date and upon the CUSIP eligibility of the Warrant Shares and on or prior to the close of business on the Termination Date but not thereafter, to subscribe for and purchase from Theralink Technologies, Inc., a Nevada corporation , of up to [ ] shares of the Company’ s Common Stock, par value $0.0001 per share . This Warrant is being issued in connection with the Securities Purchase Agreement, dated November [ ], 2021 by and between the Company and the Holder pursuant t...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of November 1, 2021, between Theralink Technologies, Inc., a Nevada corporation , and each investor identified on the signature pages to this Agreement . WHEREAS, the Company is seeking to raise a maximum of $3 million in an offering of Notes and Warrants to investors ; WHEREAS, the Investor desires to purchase from the Company a convertible promissory note, in the form attached hereto as Exhibit A , which Note shall be convertible into the Company’ s common stock, par value $0.0001 per share , in accordance with its terms; WHEREAS, in connection with the Offering, the Company will issue warrants to purchase shares of Common Stock in an amount equal to 20% of the number of the total shares of Common Stock converti..." |
|
|
|
|